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3Abstract 
Background: 
Elimination of congenital rubella syndrome depends not only on effective 
childhood immunization but also on the identification and immunization of 
rubella susceptible women. We assessed rubella susceptibility among pregnant
women and evaluated the adherence and response to postpartum 
immunization with measles, mumps and rubella (MMR) vaccine.
Methods: 
Cross-sectional study of women who gave birth at the Hospital Clinic de 
Barcelona (Spain) between January 2008 and December 2013. Antenatal 
serological screening for rubella was performed in all women during pregnancy. 
In rubella-susceptible women, two doses of MMR vaccine were recommended 
following birth. We evaluated rubella serological response to MMR vaccination 
in mothers who complied with the recommendations.
Results:
A total of 22,681 pregnant women were included in the study. The mean age 
was 32.3 years (SD 5.6), and 73.6% were primipara. The proportion of 
immigrants ranged from 43.4% in 2010 to 38.5% in 2012. The proportion of 
women susceptible to rubella was 5.9% (1328). Susceptibility to rubella 
declined with increasing maternal age. Immigrant pregnant women were more 
susceptible to rubella (7.6%) than women born in Spain (4.6%). Multivariate 
analyses showed that younger age (≤ 19 years) aOR 1.7 (95% CI 1.1- 2.5), 
primiparas aOR 1.3 (95% CI 1.1-1.5) and immigrant women aOR 1.6 (95% CI 
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41.4-1.8) were more likely to be susceptible. The second dose of MMR vaccine 
was received by 57.2% (718/1256) of rubella-susceptible women, with the 
highest proportion being immigrant women compared with women born in 
Spain. After vaccination, all women showed rubella immunity.
Conclusions: 
The higher rubella susceptibility found in the three youngest age groups and in 
immigrant women highlights the relevance of antenatal screening, in order to 
ensure identification and postpartum immunization. The postpartum 
immunization strategy is an opportunity to protect women of childbearing age 
and consequently prevent occurrence of CRS, and to increase vaccination 
coverage against rubella and other vaccine-preventable diseases. 
Keywords: rubella; pregnancy; susceptibility; postpartum immunization; 
adherence; MMR vaccine.
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5Main text
Introduction
Rubella infection occurring just before conception and during early pregnancy 
may result in miscarriage, fetal death, or congenital defects known as 
congenital rubella syndrome (CRS) [1–4]. The extent of the involvement 
depends on the time of pregnancy at which infection occurs. The highest risk of 
CRS is found in countries with high rates of rubella susceptibility among women
of childbearing age[2]. 
In 1998, the World Health Organization (WHO) European Region approved the 
aims of eliminating indigenous measles and rubella, and controlling congenital 
rubella [2,5,6]. The most important strategy for preventing rubella is 
immunization of susceptible individuals. However, individuals may be 
immunized by past vaccination or natural infection [2]. The effectiveness of the 
rubella vaccine has been demonstrated by the elimination of rubella and CRS 
from the Region of the Americas [2,7]. The aim of interrupting the endemic 
transmission of measles and rubella in Europe in 2015 will only be achieved 
with a high coverage of vaccination (> 95% with two doses of measles, mumps 
and rubella (MMR) vaccine) in all geographical areas and all population groups, 
together with a high-quality surveillance system [8]. 
Post-delivery vaccination strategies should include MMR vaccination in women 
susceptible to these diseases. In susceptible pregnant women, immunization  
with this live attenuated vaccine should be administrated during the postpartum 
period [2,9,10].
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6In Spain, rubella is a notifiable disease and is monitored through the Spanish 
Surveillance System [11]. Reported cases of rubella in 2012 were the highest 
since 2008 (64 confirmed cases: 0.14 cases per 100,000 inhabitants) and most 
cases occurred in unvaccinated adolescents and young adults. In the 2008-
2012 period, 4 rubella outbreaks and 3 cases of CRS have been recorded in 
immigrants from countries where the rubella vaccine is not routinely 
administered in childhood [8]. Although the viral circulation of rubella in Spain is 
supposedly low, it is important to monitor rubella susceptibility, especially in 
immigrant women, given the observed increase in the immigrant population in 
recent years, with Spain being one of the main receptor countries in the 
European Union [12]. In Catalonia, the region where this study was conducted, 
all pregnant women are screened for rubella antibodies in the first antenatal 
blood test [11,13].
The objectives of this study were to assess rubella susceptibility in the antenatal
rubella serology screening; to identify factors associated with susceptible 
women and to evaluate the adherence and the immunological response to 
postpartum immunization strategy with MMR vaccine in rubella susceptible 
women.
Materials and Methods
Study characteristics
We made a cross-sectional study of women who gave birth at the Hospital 
Clinic of Barcelona (HCB) between January 2008 and December 2013. 
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7Rubella immunization practices
In Catalonia, an autonomous region in the northeast of Spain with nearly 7.5 
million inhabitants, rubella-containing vaccine was introduced into the routine 
immunization schedule in 1978 for all girls aged 11 years (women born after 
1967) [14]. In 1980, in order to improve measles control, the MMR vaccine was 
introduced in children aged 15 months. In 1987, the MMR replaced the rubella 
vaccine at 11 years of age. In 1998, the age of administration of the second 
MMR dose was advanced from 11 to 4 years. Finally, in 2008, it was 
recommended that the age of administration of the first dose of MMR should be 
changed from 15 to 12 months [15]. Similar schedules for rubella-containing 
vaccine have been introduced in other Spanish regions [8]. 
Laboratory methods
Following the recommendations of the Department of Health of Catalonia, 
serological screening for rubella was made in all pregnant women during their 
first blood test, which is usually made during the first trimester of pregnancy 
[13]. Levels of rubella IgG antibodies were determined using the ADVIA® 
Centaur G™ Rubella Assay (Siemens Healthcare Diagnostics Inc.). The 
immune status was determined using the following cut-off values: <15.0 IU/ml 
(Susceptible), ≥15 IU/ml (Immune). According to the manufacturer, the 
sensitivity and specificity of the method are 97.2% and 99.5%, respectively. The
intra-assay and inter-assay coefficients are less than 5% and 6.1%, 
respectively. All samples were analyzed at the HCB microbiology laboratory.
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8In women susceptible to rubella, two doses of MMR vaccine were 
recommended in the postpartum period. The vaccine used was Priorix 
(GlaxoSmithKline, S.A.) which contains live attenuated measles, mumps and 
rubella viruses [16]. The first dose was administered in the immediate 
postpartum period, before discharge. After a minimum of one month, a visit was 
scheduled at the Adult Vaccination Centre (AVC) of the HCB for the 
administration of the second dose of MMR vaccine. A postvaccination sample 
was obtained approximately one month later in the AVC to assess rubella 
antibody titers. Only mothers who returned to the AVC to determine the 
postvaccination immunological response were included in the immunogenicity 
assessment. 
Collection of variables
Variables were limited to information recorded in the medical records, including 
maternal date of birth, country of birth, parity, delivery date, date of 
administration of first and second dose of MMR vaccine, and date of post-
vaccination blood sample. All women not born in Spain were considered 
immigrants. Rubella antibody levels during pregnancy were established as the 
main endpoint and adherence to the second MMR dose and post-vaccination 
rubella response as the secondary endpoints. We merged data extracts from 
medical information systems from Maternal-Fetal Medicine department and the 
AVC. 
Statistical Analysis
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9In the univariate analysis, absolute frequencies and percentages were used to 
describe categorical variables and means and standard deviation (SD) or 95% 
confidence intervals (CI) to describe quantitative variables with a normal 
distribution, and medians and interquartile range otherwise. We calculated the 
proportion of women susceptible to rubella with the odds ratios (OR) and 95% 
CI. To determine variables independently associated with rubella susceptibility 
and adherence to MMR immunization, the crude odds ratios were calculated for
different variables. For each variable studied, we took the group with the lowest 
rubella susceptibility as the reference group. Odds ratios were adjusted using 
multiple logistic regression analysis. The statistical analysis was performed 
using the STATA ® statistical package v12.1. Statistical significance was 
established as <0.05.
Ethical considerations
The study investigators followed the principles of the Declaration of Helsinki.  
Since this study is based on routinely collected medical records, individual 
informed consent was not obtained. Patient records/information were 
anonymized and de-identified prior to analysis. The study was approved by the 
HCB Clinical Research Ethics Committee (HCB/2014/0619).
Results
Characteristics of the study population
A total of 22,681 pregnant women were included in the study. The number of 
deliveries decreased during the study period, from 4,394 in 2008 to 3,298 in 
2013. The mean age of all participants was 32.3 years (DE 5.6) and 73.6% 
17
18
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
10
were primiparas. The proportion of immigrants ranged from 43.4% in 2010 to 
38.5% in 2012. Sixty-seven percent of patients were born in Europe, followed 
by the Americas (17.5%). By country, 58.5% were born in Spain, 10.7% 
(1,010/9,413) in China, 10.2% (962/9,413) in Morocco and 6.9% (651/9,413) in 
Ecuador. The demographic characteristics are shown in Table 1.
Factors associated with susceptibility to rubella
During the study period, 87.9 % (19,925), 11.5% (2,601) and 0.7% (148) of 
pregnant women had one, two or three rubella serology tests, respectively 
(corresponding to different pregnancies). Of the 1,328 susceptible women, 46% 
(611) were born in Spain, 9.6% (128) in China, 5.7% (76) in Morocco, and 4.4% 
(58) in the Philippines. Total susceptibility to rubella was 5.9% (1,328). There 
was a variation in susceptibility by year, ranging from 3.6% in 2008 to 7.6% in 
2011 (p <0.001) (Figure 1). The highest susceptibility rate was in the <20 years 
age group, with an overall susceptibility of 8%. Susceptibility to rubella declined 
with increasing maternal age, with women aged ≥40 years having the lowest 
susceptibility (4.4%). Immigrant women had  higher susceptibility (7.6%) than 
pregnant women born in Spain (4.6%), OR 1.7 (95% CI 1.5-1.9). Table 2 and 3:
univariate and multivariate analyses showed that the age group, parity, and the 
region of birth were independently associated with the prevalence of rubella 
antibodies. Women were more likely to be susceptible if they were younger (≤ 
19 years, aOR 1.7 (95% CI 1.1- 2.5)), primiparas aOR 1.3 (95% CI 1.1-1.5) or 
not born in Spain aOR 1.6 (95% CI 1.4-1.8). A total of 94.6% (1256/1328) of 
women susceptible to rubella received the first dose of MMR vaccine. 
Factors associated with adherence to the second dose of MMR vaccine
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A total of 57.2% (718/1256) of women susceptible to rubella received the 
second dose of MMR vaccine. The median time between the first and second 
doses was 43 days. Adherence was 29.7% and 40.1% in women aged ≤19 
years and 20-24 years, respectively. Adherence was >50% in women aged >  
30 years. During the entire study period, women born in Spain were less 
adherent to the second dose than immigrant women (52.7% vs. 55.2%) but this 
proportion changed in the last year of the study (58.0% vs. 55.3%) (Figure 2). 
After stratification by region of origin, women born in the rest of Europe, Africa 
and the Americas had lower adherence than Spanish women. Asian women 
were more likely to receive the second dose, compared to women born in Spain
(OR 1.6 (95% CI 1.2-2.2)) (Table 3). Women who gave birth in 2013 were more 
likely to receive the second dose compared with those who gave birth in 2008, 
OR 1.9 (95% CI 1.2-2.8).
Immunological response to two doses of MMR vaccine.
Around 60% (429/718) of women who received the second MMR dose returned 
for the assessment of the antibody response. After the two doses of MMR, all 
women showed protective antibody titers (≥15 IU/ml) against rubella.
Discussion
To our knowledge this is the largest study assessing rubella susceptibility 
among pregnant women in Spain, and the only one evaluating vaccine 
adherence and immunological response to the second MMR dose in the 
postpartum period. Our results showed that overall rubella susceptibility among 
22,681 pregnant women between 2008 and 2013 was 5.9%, and was 7.6% in  
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immigrant women. These numbers are higher than the susceptibility of 5% 
recommended by the WHO European Region within the aim of interrupting the 
endemic transmission of measles and rubella in Europe by 2015 [17,18].
Previous Spanish studies have reported rubella antibody prevalence ranging 
from 88.3% to 94.8%[15,19–22], and our results are within this range (94.1%). 
Recent studies in other European countries reported similar data: the 
prevalence observed in Norway was 94.4% [23] and in England between 
94.9%[24] and 97.4%[25]. In the United States, the prevalence was 91.5% [26], 
while in Canada the prevalence was 93.2% in Canadian-born mothers but was 
lower in immigrants from Northern Africa, the Middle East, China and the South 
Pacific [27]. 
In recent years, the incidence of rubella has been very low in Spain, with limited
outbreaks among immigrants from Eastern European countries [8,14,28–30]. As
a consequence, the lack of natural boosting due to an absence of circulating 
virus may result in higher susceptibility, particularly among younger women [31].
Higher susceptibility may also reflect a decline in the antibody levels from 
childhood vaccinations, as this cohort would have been eligible for two doses of 
rubella-containing vaccine, although data from surveillance of rubella and CRS 
suggest that waning immunity with increased susceptibility to rubella does not 
occur [10,25,32,33]. In 2012, Spanish national coverage of the first dose of 
MMR vaccine in infants was > 95%, but only 90% for the second dose[34]. 
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13
Women aged ≥40 years, who were born before the introduction of the rubella 
vaccination program in 1967, had a significantly-lower susceptibility to rubella 
than those born later. The significant increase in immunity with increasing 
maternal age (p<0.001) may be attributable to an increase in past exposure to 
natural infection, and to greater opportunities for immunization in the  
childbearing years, either as a result of pre-conception screening or in the post-
partum period. Women in older age groups are also more likely to be multipara 
and therefore to have been offered postpartum vaccination. 
Increased travel to and from countries with circulating rubella, combined with 
social interaction with populations presenting lower levels of rubella-specific 
antibodies, may give rise to local outbreaks when protection falls below 90% 
[25,35]. In the present study, immigrant pregnant women presented greater  
susceptibility to rubella (7.6%) compared to those born in Spain (4.6%). These 
findings were also observed in other Western European countries[19,20,36]. It 
is reported that the African and South-East Asian regions have the highest 
estimated number of CRS cases and also have the lowest uptake of the 
vaccine[2]. In our study, women born in Asia had the greatest susceptibility 
(10.8%) to rubella. Similar results were observed in other Spanish studies 
where susceptibility in Asian women was 7.7% [22] and 10.4%[36], respectively.
Many hospitals have adopted standing orders for women not immune to rubella:
post-partum standing orders have been shown to be effective in increasing 
rubella immunization among non-immune women, prior to hospital 
discharge[31]. We found good acceptance from susceptible women although 
adherence to the second dose was less than 55%. One reason for this may be 
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that it is difficult to motivate adults to be vaccinated, particularly when there are 
no outbreaks [37]. Language barriers may also affect adherence, but this was 
not the case in our study, as immigrant women from Asia had greater 
adherence. We observed an increase in adherence over the study period from 
41.1% (2008) to 67.6% (2012). This may be related to improvements in the 
postpartum immunization strategy, including better coordination between 
Maternal-Fetal Medicine department and the AVC. 
It is reported that all licensed rubella vaccines induce seroconversion rates of 
approximately 95% or higher after a single dose [2]. In our case, all pregnant 
women were immune after the second postpartum MMR vaccination, confirming
the high immunogenicity of the vaccine in this population.
Our study has some limitations. First, the serological results do not distinguish 
between vaccine- and disease-induced immunity. However, as rubella is not 
endemic in Spain and the number of cases has decreased dramatically in the 
last 30 years [8], our results are probably a true reflection of  vaccine-induced 
immunity. Secondly, the length of residence in Spain of immigrant pregnant 
women was not available, and consequently they may have received 
vaccination according to the Spanish routine immunization schedule. Thirdly, 
there was no available information on previously-administered doses of vaccine 
with the rubella component, or on rubella immunization policies in other  
countries. Likewise, the second dose might have been administered in other 
health facilities, which would mean adherence would be greater than shown by 
our results. Finally, since not all women returned for the postvaccination 
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serology, we were not able to assess the vaccine response in all vaccinated 
women.
Conclusions
The higher rubella susceptibility found in the three youngest age groups and in 
immigrant women highlights the relevance of antenatal screening, in order to 
ensure identification and postpartum immunization of rubella susceptible 
women. In the context of Spain, with observed increase in immigrant population 
in recent years, the postpartum immunization strategy is an opportunity to 
protect women of childbearing age and to increase vaccination coverage 
against rubella and other vaccine-preventable diseases. Consequently, MMR 
vaccination would reinforce the achievement of eliminating endemic rubella and 
measles in the European region.
Acknowledgments
The authors wish to thank Consolación Diez, Guillermo Mena, Marta Aldea, 
Víctor Guillermo Sequera, César Velasco, Víctor García, Fernando Do Pazo, 
José Miguel Sotoca, Eugenia Balsach and all the obstetricians and midwifes 
from the Maternal-Fetal Medicine department for their support to postpartum 
vaccination program. 
29
30
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
16
References
[1] Reef SE, Plotkin SA. Rubella vaccine. In: Plotkin S, Orsenstein W, Offit P, 
editors. Vaccines. 6th ed., Philadelphia: Saunders Elsevier; 2012, p. 688–
718.
[2] World Health Organization. Rubella vaccines: WHO position paper—
Recommendations. Vaccine 2011;29:8767–8.
[3] Miller E, Cradock-Watson J, Pollock T. Consequences of confirmed 
maternal rubella at successive stages of pregnancy. Lancet 1982;2:781–
4.
[4] Enders G, Nickerl-Pacher U, Miller E, Cradock-Watson J. Outcome of 
confirmed periconceptional maternal rubella. Lancet 1988;1:1445–7.
[5] WHO European Region. Eliminating measles and rubella.Framework for 
the verification process in the WHO European Region 2012. 
http://www.euro.who.int/en/health-topics/communicable-
diseases/measles-and-rubella/publications/2014/eliminating-measles-
and-rubella.-framework-for-the-verification-process-in-the-who-european-
region.
[6] WHO European Region. Eliminating measles and rubella and preventing 
congenital rubella. WHO European Region strategic plan 2005–2010 
2010. 
http://www.euro.who.int/__data/assets/pdf_file/0008/79028/E87772.pdf.
[7] Castillo-Solórzano C, Carrasco P, Tambini G, Reef S, Brana M, de 
Quadros C a. New horizons in the control of rubella and prevention of 
congenital rubella syndrome in the Americas. J Infect Dis 2003;187 
Suppl:S146–52.
[8] Centro Nacional de Epidemiología Carlos III. Informe de la vigilancia del 
Sarampión, la Rubéola y el Síndrome de Rubéola Congénita en España. 
Año 2011. Plan Nac Elimin Del Sarampión y La Rubéola 2013. 
http://www.isciii.es/ISCIII/es/contenidos/fd-servicios-cientifico-tecnicos/fd-
vigilancias-alertas/fd-enfermedades/fd-enfermedades-prevenibles-
vacunacion/Informe-Anual-Plan-Eliminacion-Sarampion-Rubeola-
2011.pdf.
[9] Domínguez A, Torner N, Martínez A, Costa J, Plans P, Ciruela P, et al. 
Rubella elimination programme strengthened through measles elimination
programme in Catalonia. Vaccine 2006;24:1433–7.
31
32
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
17
[10] Advisory Committee on Immunization Practices (ACIP). Prevention of 
Measles, Rubella, Congenital Rubella Syndrome, and Mumps. 2013. 
http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6204a1.htm.
[11] European Centre for Disease Prevention and Control. Survey on rubella, 
rubella in pregnancy and congenital rubella surveillance systems in EU / 
EEA countries. 2013. 
http://ecdc.europa.eu/en/publications/Publications/survey-rubella-
pregnancy-congenital-surveillance-systems-may-2013.pdf.
[12] Comission of the European Communities. Eurostat. 
http://epp.eurostat.ec.europa.eu/tgm/table.do?
tab=table&init=1&language=en&pcode=tps00176&plugin=1.
[13] Generalitat de Catalunya. Departament de Salut. Protocol de seguiment 
de l’embaràs a Catalunya. 2005. 
http://www20.gencat.cat/docs/canalsalut/Home Canal 
Salut/Professionals/Recursos/Protocols_i_recomanacions/17_salut_de_la
_mare_i_de_linfant/documents/protocolseguimentembaras.pdf.
[14] Secretaria de Salut Pública. Subdirecció General de Vigilància i Resposta
a Emergències en Salut Pública. Programa d’eliminació de la rubèola 
postnatal i congènita a Catalunya. 2012 i 2013. 2014. 
http://www20.gencat.cat/docs/canalsalut/Home Canal 
Salut/Professionals/Temes_de_salut/Vigilancia_epidemiologica/document
s/Arxius/anual_rubeola_2012.pdf.
[15] Borràs E, Campins M, Esteve M, Urbiztondo L, Broner S, Bayas JM, et al.
Are healthcare workers immune to rubella? Hum Vaccin Immunother 
2013;10:686–91.
[16] Ficha Técnica Priorix 2007. 
http://www.aemps.gob.es/cima/pdfs/es/ft/62314/FT_62314.pdf.
[17] Skendzel L. Rubella immunity. Defining the level of protective antibody. 
Am J Clin Pathol 1996;106:170–4.
[18] Hanon FX, Spika John J, Wassilak Steven S EN. WHO European 
Region’s strategy for elimination of measles and congenital rubella 
infection. Euro Surveill 2003;8:129–30.
[19] Vargas-Leguás H, Campins Martí M, Juste Sánchez C, Martínez Gómez 
X, Hermosilla Pérez E, Cabero Roura L. Rubella susceptibility of 
immigrant pregnant women in Catalonia | Susceptibilidad a la rubéola en 
gestantes inmigrantes con residencia en Cataluña. Med Clin (Barc) 
2009;132:344–7.
33
34
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
18
[20] Dominguez A, Plans P, Espuñes J, Costa J, Torner N, Cardeñosa N, et al.
Rubella immune status of indigenous and immigrant pregnant women in 
Catalonia, Spain. Eur J Public Health 2007;17:560–4.
[21] Domínguez A, Plans P, Costa J, Torner N, Cardenosa N, Batalla J, 
Plasencia A SL. Seroprevalence of measles, rubella, and mumps 
antibodies in Catalonia, Spain: results of a cross-sectional study. Eur J 
Clin Microbiol Infect Dis 2006;25:310–7.
[22] Hernandez Diaz R, Rodrigo Val MP, Misiego Peral A, Roc Alfaro ML, 
Adiego Sancho MB. Seroepidemiologic study of rubella in childbearing 
women in Aragon, Spain (2003-2007). Gac Sanit 2011;25:20–2.
[23] Barlinn R, Vainio K, Samdal HH, Nordbø SA, Nøkleby H, Dudman SG. 
Susceptibility to Cytomegalovirus , Parvovirus B19 and Age-Dependent 
Differences in Levels of Rubella Antibodies Among Pregnant Women 
2014;826:820–6.
[24] Mortlock S, Farthing S. Rubella antibody status of patients attending a 
south-west London antenatal clinic , 2007-2012. Br J Biomed Sci 
2014;71:111–4.
[25] Byrne L, Brant L, Reynolds C, Ramsay M. Seroprevalence of low rubella 
IgG antibody levels among antenatal women in England tested by NHS 
Blood and Transplant: 2004-2009. Is rubella susceptibility increasing? 
Vaccine 2012;30:161–7.
[26] Hyde TB, Kruszon-Moran D, McQuillan GM, Cossen C, Forghani B, Reef 
SE. Rubella Immunity Levels in the United States Population : Has the  
Threshold of Viral Elimination Been Reached? Clin Infect Dis 
2006;43:146–50.
[27] McElroy R, Laskin M, Jiang D, Shah R, Ray JG. Rates of rubella immunity
among immigrant and non-immigrant pregnant women. J Obstet 
Gynaecol Can 2009;31:409–13.
[28] Barrabeig I, Torner N, Martínez A, Carmona G, Ciruela P, Batalla J, et al. 
Results of the rubella elimination program in Catalonia (Spain), 2002-
2011. Hum Vaccin Immunother 2013;9:642–8.
[29] Torner N, Valerio L, Costa J, Parrón I DA. Rubella outbreak in young 
adults of Brazilian origin in Barcelona suburb, October-December 2005. 
Euro Surveill 2006;11.
[30] Red de Vigilancia Epidemiológica de la Comunidad de Madrid 
[Epidemiological Surveillance Network of the Autonomous Region of 
35
36
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
19
Madrid] GL. Outbreak of rubella in the Madrid region, Spain, 2005. Euro 
Surveill. Eurosurveillance 2005;10:E050707.2.
[31] Lim GH, Harris T, Desai S, Crowcroft NS, Mazzulli T, Kozlowski T, et al. 
Rubella immunity among prenatal women in Ontario, 2006--2010. BMC 
Infect Dis 2013;13:362.
[32] Pebody RG, Gay NJ, Hesketh LM, Vyse A, Morgan-Capner P, Brown DW,
et al. Immunogenicity of second dose measles-mumps-rubella (MMR) 
vaccine and implications for serosurveillance. Vaccine 2002;20:1134–40.
[33] Davidkin I, Jokinen S, Broman M, Leinikki P, Peltola H. Persistence of 
measles, mumps, and rubella antibodies in an MMR-vaccinated cohort: a 
20-year follow-up. J Infect Dis 2008;197:950–6.
[34] Ministerio de Sanidad Servicios Sociales e Igualdad. Gobierno de 
España. Coberturas de Vacunación. DATOS ESTADÍSTICOS 2014. 
https://www.msssi.gob.es/profesionales/saludPublica/prevPromocion/vac
unaciones/coberturas.htm.
[35] Carnicer-Pont D, Peña-Rey I, de Aragón VM, de Ory F, Dominguez A, 
Torner N, et al. Eliminating congenital rubella syndrome in Spain: does 
massive immigration have any influence? Eur J Public Health 
2008;18:688–90.
[36] Ramos JM, Milla A, Rodríguez JC GF. Rubella immune status among 
immigrant and nonimmigrant women in Spain. J Med Virol 2012;84:548–
50.
[37] Eason E, Naus M, Sciberras J, Oppenheimer L. Evaluation of an 
institution-based protocol for postpartum rubella vaccination. CMAJ 
2001;165:1321–3. 
37
38
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
20
Figure legends
Figure 1. Prevalence of susceptibility to rubella-specific IgG among pregnant 
women, Barcelona, 2008-2013. 
Figure 2. Adherence to the second dose of MMR vaccine among postpartum 
women by country of birth, Barcelona, 2008-2013. 
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Table 1: Demographic characteristics of pregnant women included in the study, 
Barcelona, 2008-2013. (n=22,681)
Table 2: Factors associated with susceptibility to rubella-specific IgG, 
Barcelona, 2008-2013. (n=1328)
Table 3. Adherence to two doses of MMR vaccine in women immunized 
postpartum, Barcelona, 2008-2013 (n=718).
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